One woman’s story in Dallas
In late 2022, Kristi Kennebrew, now 31 and living in Dallas, Texas, began taking Mounjaro while her then-employer covered the full cost. Over roughly a year, her weight fell from about 265 pounds to 185. She told CNBC that she became more confident, more sociable and far more energetic.
In early 2024 she lost her job and her coverage, stopped the drug abruptly, and later paid $399 a month out of pocket for another medication. In the fall of 2025 she landed a new role in recruitment marketing; her employer’s plan covers GLP-1s through a health-coaching program, and she now pays just $25 a month. For her, that brings a rare sense of security.
Drug coverage becomes a talent-retention perk
According to Gallup, about 11% of U.S. adults are taking a GLP-1 for weight loss in 2026, up sharply from 3% in 2024. Employer-sponsored insurance is the largest source of health coverage for Americans under 65, covering more than 165 million people, so each company’s decision carries special weight.
The corporate picture is clearly diverging:
- Walmart plans to offer more than 250 prescription drugs at no cost to employees from 2027, including GLP-1s for diabetes.

















